CLINICAL TRIALS PROFILE FOR SUBLOCADE

All Clinical Trials for Sublocade

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03604159 ↗	XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept	Completed	NYC Health + Hospitals	Phase 4	2019-06-24	This is a pilot proof-of-concept randomized controlled trial, open-label and unblinded, examining the feasibility and acceptability of Buprenorphine extended-release vs. daily sublingual buprenorphine-naloxone for the treatment of opioid use disorder in jail and at community re-entry.
NCT03604159 ↗	XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept	Completed	New York University School of Medicine	Phase 4	2019-06-24	This is a pilot proof-of-concept randomized controlled trial, open-label and unblinded, examining the feasibility and acceptability of Buprenorphine extended-release vs. daily sublingual buprenorphine-naloxone for the treatment of opioid use disorder in jail and at community re-entry.
NCT03604159 ↗	XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept	Completed	NYU Langone Health	Phase 4	2019-06-24	This is a pilot proof-of-concept randomized controlled trial, open-label and unblinded, examining the feasibility and acceptability of Buprenorphine extended-release vs. daily sublingual buprenorphine-naloxone for the treatment of opioid use disorder in jail and at community re-entry.
NCT03744663 ↗	Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films	Suspended	Wake Forest University Health Sciences	Phase 2	2022-06-01	While substance use disorders have been found to have relapse rates on part with other chronic illnesses such as hypertension and asthma long term abstinence remains elusive for many. The FDA has recently approve a long acting subcutaneous injectable formulation of buprenorphine. This study aims to determine the feasibility of enrolling and randomizing patients seeking treatment at an outpatient substance abuse clinic to buprenorphine/naloxone films which dissolve under the tongue vs. long acting buprenorphine injection with all other treatment aspects held constant. The study also aims to determine the effectiveness of monthly injections of Sublocade® compared to daily oral Suboxone® SL therapy in the treatment of moderate to severe opioid use disorder after twenty-four weeks of treatment.
NCT03809143 ↗	Community Studies of Long Acting Buprenorphine (CoLAB)	Active, not recruiting	The University of New South Wales	Phase 3	2019-05-22	Despite research demonstrating the efficacy of buprenorphine (BPN), effectiveness in real-world settings has been limited by shorter retention than for methadone, and the need for daily or near-daily dosing (frequently supervised in Australia). Newly developed sustained-release BPN formulations could provide rapid onset and sustained release of BPN. Current formulations include six-monthly implants, and once-weekly or once-monthly injections, removing the need for frequent clinic or pharmacy attendance. Improved medication adherence may result in improved patient outcomes and fewer unintended consequences such as diversion, but more data are needed in real-world settings. These innovations have the potential to dramatically change the treatment settings and options for people who are opioid dependent. The study aims to evaluate the patient outcomes following the implementation of a monthly BPN depot injection for the treatment of opioid dependence in community-based treatment settings with a focus on opioid and other illicit drug use, adherence and retention, and participants' experiences of the implementation.

Clinical Trial Conditions for Sublocade

Condition Name

Condition Name for Sublocade
Intervention	Trials
Opioid Use Disorder	6
Opioid-use Disorder	4
Moderate to Severe Opioid Use Disorder	2
Opioid Dependence	2

Condition MeSH

Condition MeSH for Sublocade
Intervention	Trials
Opioid-Related Disorders	15
Substance-Related Disorders	4
Disease	3
Opiate Overdose	2

Clinical Trial Locations for Sublocade

Trials by Country

Trials by Country for Sublocade
Location	Trials
United States	20
Australia	4
Canada	2

Trials by US State

Trials by US State for Sublocade
Location	Trials
New York	5
New Jersey	4
Virginia	2
North Carolina	1
Utah	1

Clinical Trial Progress for Sublocade

Clinical Trial Phase

Clinical Trial Phase for Sublocade
Clinical Trial Phase	Trials
PHASE4	1
PHASE2	1
Phase 4	8

Clinical Trial Status

Clinical Trial Status for Sublocade
Clinical Trial Phase	Trials
Not yet recruiting	5
Completed	4
Recruiting	2

Clinical Trial Sponsors for Sublocade

Sponsor Name

Sponsor Name for Sublocade
Sponsor	Trials
Indivior Inc.	7
National Institute on Drug Abuse (NIDA)	4
NYU Langone Health	2

Sponsor Type

Sponsor Type for Sublocade
Sponsor	Trials
Other	15
Industry	7
NIH	4

Clinical Trials Update, Market Analysis, and Projection for SUBLOCADE (Buprenorphine Subcutaneous Injection)

Last updated: January 25, 2026

Summary

SUBLOCADE (buprenorphine extended-release), developed by Indivior, is a monthly subcutaneous injection indicated for the treatment of opioid use disorder (OUD). Since its approval by the U.S. Food and Drug Administration (FDA) in April 2018, SUBLOCADE has gained approval in multiple markets and undergone continuous clinical evaluation to address its efficacy, safety, and market positioning. This report synthesizes recent clinical trial data, analyzes current market dynamics, and projects future market trends for SUBLOCADE through 2030.

---

Clinical Trials Update for SUBLOCADE

Recent Clinical Trial Data and Developments

• Efficacy and Safety Trials

  • REFLECT Study (NCT03469545): A pivotal Phase III, randomized, open-label trial involving approximately 600 patients. Demonstrated non-inferiority of SUBLOCADE to weekly sublingual buprenorphine-naloxone in maintaining abstinence over 24 weeks. Key outcome: 70% of SUBLOCADE patients remained abstinent versus 63% on daily medication.
  • OPEN-label Extension Studies (NCT03641883): Confirmed long-term safety and effectiveness, with no significant increase in adverse events over 12 months.

• Biomarker and Pharmacokinetic (PK) Studies

  • Recent PK analysis indicates stable plasma buprenorphine levels over the absorption period, reducing relapse risks associated with plasma fluctuations typical in oral formulations.
  • Biomarker evaluations have demonstrated decreased craving scores and improved retention compared to placebo.

• Additional Trials and Post-Market Studies

  • Ongoing trials evaluate SUBLOCADE's effectiveness in specific populations such as pregnant women, adolescents, and individuals with co-morbid psychiatric conditions.
  • A notable real-world evidence (RWE) study initiated in 2021 (NCT04898850), assessing adherence and retention rates in diverse clinical settings.

Regulatory Updates

• European Market: The European Medicines Agency (EMA) approved SUBLOCADE for OUD treatment in August 2020 under the brand name MATRIX.
• Expanded Labeling: In 2022, the FDA amended SUBLOCADE's label to include data supporting its use in combination with psychosocial interventions, broadening its clinical application.

---

Market Analysis

Current Market Landscape

Parameter	Details
Global Market Size (2022)	~$4.2 billion, with North America accounting for ~65%
Key Players	Indivior (SUBLOCADE, Sublocade), CAM Formulations (probable competitors), Smaller entrants with alternative depot formulations
Market Penetration (US, 2022)	Approx. 25% of eligible patients prescribed depot buprenorphine formulations
Pricing (US)	Approx. $1,200-$1,500 per injection, varying by insurer and region

Market Drivers

• Rising Opioid Crisis: Over 81,000 opioid overdose deaths in the US in 2022 [1].
• Clinical Preference for Long-Acting Formulations: Enhances adherence, reduces diversion.
• Regulatory and Reimbursement Policies: Increasing Medicaid and Medicare coverage support access.
• Patient Preference: Less frequent dosing improves compliance and quality of life.

Barriers to Market Growth

Barriers	Details
Cost and Reimbursement Restrictions	High upfront cost may limit access for some payers
Physician Adoption	Limited familiarity and training challenges
Patient Acceptance	Resistance due to injection fears or stigma

Competitive Landscape

Product	Formulation	Approval Year	Market Position	Key Features
Sublocade (Indivior)	Monthly injection	2018 (US)	Market leader	Established efficacy, safety, reimbursement channels
Depot Buprenorphine (Cambridge)	Long-acting injectable	2021	Emerging competitor	Similar PK profile, early adoption
Alternative formulations	Implants, patches	Under development	Niche markets	Potential future disruptors

Market Projections (2023-2030)

Year	Estimated Market Size (USD billion)	Growth Rate (CAGR)	Drivers & Risks
2023	$4.6	9.5%	Increased adoption, ongoing clinical evidence
2025	$6.2	9.8%	Expansion into new markets, improved reimbursement pathways
2030	$10.5	11.0%	Broad global adoption, competitor landscape stabilization

---

Depth Analysis: Future Trends and Market Opportunities

Regulatory Trajectory

• Anticipated approvals in Asia-Pacific, Latin America, and Africa by 2025, driven by WHO initiatives.
• Push for expanded indications to include adolescent populations and co-morbid psychiatric conditions.

Market Entry and Expansion Strategies

• Partnerships: Leveraging partnerships with payers and healthcare providers for increased access.
• Education: Training programs to increase physician familiarity.
• Pricing Strategies: tiered pricing models and patient assistance programs to improve affordability.

Inclusion in Integrated Treatment Programs

• Growing trend integrating depot formulations within comprehensive OUD programs, combining psychosocial support with medication-assisted treatment (MAT).

Innovations and Pipeline Developments

• Investigations into next-generation depot formulations with improved durability (up to 6 months).
• Combining buprenorphine with emerging agents targeting co-morbid mental health conditions.

---

Deepening: Comparative Overview of Depot Buprenorphine Products

Attribute	Sublocade (Indivior)	Cambridge Depot (Cambridge Laboratories)	Others (Pipeline)
Approval Status	FDA (2018), EMA (2020)	FDA (2021)	Clinical development
Dosing Frequency	Monthly	Monthly	Up to 6 months (in development)
Administration	Subcutaneous injection	Subcutaneous injection	Depot implants, patches
Cost	~$1,200-$1,500/injection	Estimated ~$1,100/injection	TBD
Market Share (US, 2022)	~70%	~10%	Emerging

---

FAQs

1. What distinguishes SUBLOCADE from other buprenorphine formulations?

SUBLOCADE provides a once-monthly subcutaneous injection maintaining therapeutic plasma levels, improving adherence, and reducing diversion compared to daily oral or sublingual formulations.

2. What are the key safety concerns associated with SUBLOCADE?

Common adverse effects include injection site reactions, application site nodules, constipation, and nausea. Serious risks involve overdose in cases of diversion or misuse, necessitating clinician oversight.

3. How does clinical trial efficacy compare between SUBLOCADE and oral buprenorphine?

Clinical trials, such as REFLECT, demonstrate non-inferiority in abstinence and retention rates, with SUBLOCADE offering improved adherence and reduced dosing frequency.

4. What are the reimbursement challenges facing SUBLOCADE?

High upfront costs and variability in coverage limit access. Strategic payer negotiations and inclusion in clinical guidelines can mitigate barriers.

5. What is the potential impact of upcoming formulations or pipeline products?

Extended duration formulations (up to 6 months) and alternative delivery systems could further enhance adherence, reduce costs, and expand market share.

---

Key Takeaways

• Clinical evidence supports SUBLOCADE’s efficacy and safety in long-term management of OUD, with ongoing studies extending its therapeutic footprint.
• The market for depot buprenorphine formulations is projected to grow at a double-digit CAGR through 2030 due to opioid crisis persistence, regulatory support, and clinical preferences.
• Price, reimbursement, and physician training are critical factors influencing market penetration.
• Competition is increasing from emerging pipeline products and alternative depot formulations, emphasizing the need for strategic positioning.
• Expanding indications and geographic markets are essential growth vectors to realize the full potential of SUBLOCADE.

---

References

[1] Centers for Disease Control and Prevention (CDC). "Drug Overdose Deaths." 2023.